Last reviewed · How we verify
Aceclidin (ACECLIDINE)
VIZZ, a pupil-selective miotic, contracts the iris sphincter muscle to improve vision by extending depth of focus.
Aceclidine is a marketed miotic agent specifically designed to treat presbyopia by contracting the iris sphincter muscle to enhance depth of focus. Its key competitive advantage lies in its selective mechanism of action, which differentiates it from older, off-patent drugs like pilocarpine and carbachol. The primary risk is the key composition patent expiry in 2028, which could lead to increased competition from generics.
At a glance
| Generic name | ACECLIDINE |
|---|---|
| Sponsor | Lenz Therap |
| Drug class | aceclidine |
| Target | muscarinic receptors |
| Modality | Small molecule |
| Therapeutic area | Neuroscience |
| Phase | FDA-approved |
Mechanism of action
VIZZ works by selectively interacting with the iris and causing the iris sphincter muscle to contract. This contraction creates a pinhole effect, which extends the depth of focus and improves vision.
Approved indications
- Presbyopia
Common side effects
- instillation site irritation
- dim vision
- headache
- conjunctival hyperemia
- ocular hyperemia
Key clinical trials
- Phase 3 Efficacy Study of LNZ100 & LNZ101 for the Treatment of Presbyopia (PHASE3)
- Phase 3 Evaluation of the Safety and Efficacy of LNZ100 & LNZ101 for the Treatment of Presbyopia (PHASE3)
- Evaluation of the Efficacy and Safety of LNZ101 and LNZ100 for the Presbyopia (PHASE3)
- Phase 3 Safety Study for the Treatment of Presbyopia Subjects (PHASE3)
- Evaluation of the Safety and Effectiveness of Aceclidine (LNZ101) and Aceclidine + Brimonidine (LNZ100) in the Treatment of Presbyopia (PHASE2)
- Evaluation of the Safety and Effectiveness of Aceclidine/Brimonidine (LNZ101) and Aceclidine (LNZ100) in the Treatment of Presbyopia (PHASE2)
- Safety, Tolerability and Pharmacokinetics of LNZ101 and LNZ100 Ophthalmic Solutions in Healthy Adult Chinese With Presbyopia (PHASE1)
- Plasma Pharmacokinetics and Safety of LNZ101 and LNZ100 Ophthalmic Solutions in Healthy Adult Subjects With Presbyopia (PHASE1)
Patents
| Patent | Expiry | Type |
|---|---|---|
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
| FDA Orange Book | Patents + exclusivity |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Aceclidin CI brief — competitive landscape report
- Aceclidin updates RSS · CI watch RSS